Contact

Information on PDMR transaction in PAXMAN AB (publ)

PAXMAN AB (publ) (“PAXMAN” or the “Company”) announces that the Company’s shareholder Björn Littorin has sold 300,000 shares in the Company. The acquiror has agreed to not divest any of the acquired shares, subject to customary exceptions, for a period of 180 days from 21 December 2021[1].

Following the transaction, Björn Littorin owns 465,076 shares in the Company and has agreed to not divest any additional shares, subject to customary exceptions, for period of 180 days from 21 December 2021[1].

[1] In connection with the directed share issue carried out by Paxman in 16 December 2021, Björn Littorin entered into a lock-up undertaking of 180 days from the settlement date on future divestments of shares in the Company, subject to certain conditions. The acquiror of Björn Littorin’s shares has overtaken Björn Littorin’s lock-up undertaking with regards to the acquired shares.

Information on PDMR transaction in PAXMAN AB (publ) Information on PDMR transaction in PAXMAN AB (publ)
What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram